Effect of probiotics on clinical and immune parameters in enthesitis-related arthritis category of juvenile idiopathic arthritis

Clinical and Experimental Immunology

Volumn 185, Issue 3, 2016, Pages 301-308

  Shukla, A ^a   Gaur, P ^a   Aggarwal, A ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

clinical trial; cytokine; juvenile arthritis; outcome measures; probiotics

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA; VSL3;

ABDOMINAL PAIN; ADOLESCENT; ARTHRITIS; ARTICLE; BACKACHE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG WITHDRAWAL; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLATULENCE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; INFECTION; INTESTINE FLORA; JUVENILE RHEUMATOID ARTHRITIS; LOSS OF APPETITE; MALE; MORNING STIFFNESS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SACROILIITIS; SKIN INFECTION; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UVEITIS;

EID: 84983268272     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12818     Document Type: Article

References (40)

1. Petty RE, Southwood TR, Manners P et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J Rheumatol 2004; 31:390–2.
2. Colbert RA. Classification of juvenile spondyloarthritis: enthesitis-related arthritis and beyond. Nat Rev Rheumatol 2010; 6:477–85.
3. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007; 369:767–78.
4. Picco P, Gattorno M, Marchese N et al. Increased gut permeability in juvenile chronic arthritides. A multivariate analysis of the diagnostic parameters. Clin Exp Rheumatol 2000; 18:773–8.
5. Orlando A, Renna S, Perricone G, Cottone M. Gastrointestinal lesions associated with spondyloarthropathies. World J Gastroenterol 2009; 15:2443–8.
6. Saurenmann RK, Rose JB, Tyrrell P et al. Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum 2007; 56:1974–84.
7. Stoll ML, Kumar R, Morrow CD et al. Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis. Arthritis Res Ther 2014; 16:486.
8. Gill T, Asquith M, Rosenbaum JT, Colbert RA. The intestinal microbiome in spondyloarthritis. Curr Opin Rheumatol 2015; 27:319–25.
9. Lin P, Bach M, Asquith M et al. HLA-B27 and human β2-microglobulin affect the gut microbiota of transgenic rats. PLOS ONE 2014; 9:e105684.
10. Rosenbaum JT, Davey MP. Hypothesis: time for a gut check: HLA B27 predisposes to ankylosing spondylitis by altering the microbiome. Arthritis Rheum 2011; 63:3195–8.
11. Arvonen M, Virta LJ, Pokka T, Kröger L, Vähäsalo P. Repeated exposure to antibiotics in infancy: a predisposing factor for juvenile idiopathic arthritis or a sign of this group's greater susceptibility to infections? J Rheumatol 2015; 42:521–6.
12. Schultz M, Veltkamp C, Dieleman LA et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis 2002; 8:71–80.
13. Borruel N, Carol M, Casellas F et al. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002; 51:659–64.
14. Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124:1202–9.
15. Kruis W, Fric P, Pokrotnieks J et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53:1617–23.
16. Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol 2008; 43:842–8.
17. Jenks K, Stebbings S, Burton J, Schultz M, Herbison P, Highton J. Probiotic therapy for the treatment of spondyloarthritis: a randomized controlled trial. J Rheumatol 2010; 37:2118–25.
18. Kalina WV, Mohamadzadeh M. Lactobacilli as natural enhancer of cellular immune response. Discov Med 2005; 5:199–203.
19. Picard C, Fioramonti J, Francois A, Robinson T, Neant F, Matuchansky C. Review article: bifidobacteria as probiotic agents – physiological effects and clinical benefits. Aliment Pharmacol Ther 2005; 22:495–512.
20. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104:437–43.
21. Fedorak RN, Feagan BG, Hotte N et al. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. Clin Gastroenterol Hepatol 2015; 13:928–35.
22. Sieper J, van der Heijde D, Landewé R et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 2009; 68:784–8.
23. Tonks S, Marsh SG, Bunce M, Bodmer JG. Molecular typing for HLA class I using ARMS-PCR: further developments following the 12th International Histocompatibility Workshop. Tissue Antigens 1999; 53:175–83.
24. Weiss PF, Colbert RA, Xiao R et al. Development and retrospective validation of the juvenile spondyloarthritis disease activity index. Arthritis Care Res (Hoboken) 2014; 66:1775–82.
25. Saez-Lara MJ, Gomez-Llorente C, Plaza-Diaz J, Gil A. The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed Res Int 2015; 2015:505878.
26. Vaghef-Mehrabany E, Alipour B, Homayouni-Rad A, Sharif SK, Asghari-Jafarabadi M, Zavvari S. Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. Nutrition 2014; 30:430–5.
27. Alipour B, Homayouni-Rad A, Vaghef-Mehrabany E et al. Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial. Int J Rheum Dis 2014; 17:519–27.
28. Pineda ML, Thompson SF, Summers K, de Leon F, Pope J, Reid G. A randomized, double-blinded, placebo controlled pilot study of probiotics in active rheumatoid arthritis. Med Sci Monit 2011; 17:CR347–54.
29. Brophy S, Burrows CL, Brooks C, Gravenor MB, Siebert S, Allen SJ. Internet-based randomized controlled trials for the evaluation of complementary and alternative medicines: probiotics in spondyloarthropathy. BMC Musculoskelet Disord 2008; 9:4
30. Fujimori S, Tatsuguchi A, Gudis K et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol 2007; 22:1199–204.
31. Steed H, Macfarlane GT, Blackett KL et al. Clinical trial: the microbiological and immunological effects of synbotic consumption – a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 2010; 32:872–83.
32. Howarth GS, Wang H. Role of endogenous microbiota, probiotics and their biological products in human health. Nutrients 2013; 5:58–81.
33. Matsumoto S, Hara T, Hori T et al. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 2005; 140:417–26.
34. Zheng B, van Bergenhenegouwen J, Overbeek S et al. Bifidobacterium breve attenuates murine dextran sodium sulfate-induced colitis and increases regulatory T cell responses. PLOS ONE 2014; 9:e95441.
35. Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol 2005; 174:3237–46.
36. Scher JU, Sczesnak A, Longman RS et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2013; 2:e01202.
37. Costello ME, Ciccia F, Willner D et al. Intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol 2015; 67:686–91.
38. Yatsunenko T, Rey FE, Manary MJ et al. Human gut microbiome viewed across age and geography. Nature 2012; 486:222–7.
39. Kroon FP, van der Burg LR, Ramiro S et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev 2015; 7:CD010952.
40. Rogers MA, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect 2016; 22:178.e1–9.